Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Acetylcysteine

Acetylcysteine
Contact us for more batch information
Select Batch
Purity:100%
Resource Download

Acetylcysteine

Catalog No. T0875Cas No. 616-91-1
Acetylcysteine (NAC) is an N-acetyl derivative of cysteine, a ROS inhibitor and mucolytic agent. Acetylcysteine induces apoptosis, can be used to reduce mucus thickness, and has anti-influenza viral activity.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
5 g$33In Stock
10 g$42In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Acetylcysteine"

Product Introduction

Bioactivity
Description
Acetylcysteine (NAC) is an N-acetyl derivative of cysteine, a ROS inhibitor and mucolytic agent. Acetylcysteine induces apoptosis, can be used to reduce mucus thickness, and has anti-influenza viral activity.
In vitro
METHODS: Human bladder cancer cells T24 were treated with Acetylcysteine (5-50 mM) for 24 h. Cell viability was measured by MTT.
RESULTS: Acetylcysteine dose-dependently inhibited the cell viability of T24 cells with an IC50 of 33.33 mM.[1]
METHODS: Rat cardiomyocytes H9c2 were treated with Acetylcysteine (2-4 mM) for 12-24 h, and apoptosis was detected by Flow Cytometry.
RESULTS: Acetylcysteine dose- and time-dependently induced apoptosis in H9c2 cells. [2]
In vivo
METHODS: To investigate the effects on apoptotic liver injury in mice, Acetylcysteine (150 mg/kg) was administered intraperitoneally to CD-1 mice as a single injection, and GalN/LPS was used to induce hepatic injury 30 min later.
RESULTS: Acetylcysteine pretreatment significantly attenuated GalN/LPS-induced hepatocyte apoptosis.Acetylcysteine attenuates GalN/LPS-induced apoptotic liver injury through its potent ROS scavenging and anti-apoptotic effects. [3]
METHODS: To assay in vivo activity, Acetylcysteine (500 mg/kg) was administered orally to R6/1 transgenic mice with Huntington's disease (HD) once daily for nine weeks.
RESULTS: Chronic Acetylcysteine administration delayed the onset and development of motor deficits in R6/1 mice and also had antidepressant-like effects in both R6/1 and wild-type mice. [4]
Cell Research
For survival experiments, washed cells are resuspended in RPM1 1640 medium and plated in 0.5 mL at a density of 8-10×105 per well in 24 well plastic culture dishes coated with rat tail collagen. To feed, but to avoid loss of floating cells, fresh medium (0.2 mL) is added to the cultures on days 1, 5, and 10. For experiments involving 'primed' PC12 cells, cultures are pretreated for l-2 weeks with NGF in RPM1 1640 medium supplemented with 1% heat-iN-acetylcysteinetivated horse serum. The cells are then washed and passaged into serum-free RPM1 1640 medium.
Animal Research
Rats are randomly allocated into five groups: sham group (n=5), control group with IIR (n=8) and three groups with IIR who are given N-acetylcysteine in different dosages: 150 mg/kg intraperitoneally 5 min before ischemia (n=8, group N-acetylcysteine 150), 300 mg/kg i.p 5 min before ischemia (n=7, group N-acetylcysteine 300), and 150 mg/kg i.p 5 min before ischemia plus 150 mg/kg 5 min before reperfusion (n=7, group N-acetylcysteine 150 + 150). After 4 h of reperfusion, the animals are euthanized by exsanguination from the abdominal aorta.[1]
AliasN-Acetylcysteine, N-Acetyl-L-cysteine, LNAC, NAC, N-Acetyl Cysteine
Chemical Properties
Molecular Weight163.19
FormulaC5H9NO3S
Cas No.616-91-1
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 60 mg/mL (367.67 mM)
Ethanol: 31 mg/mL (190 mM)
H2O: 100 mg/ml (612.78 mM)
Solution Preparation Table
H2O/Ethanol
1mg5mg10mg50mg
1 mM6.1278 mL30.6391 mL61.2783 mL306.3913 mL
5 mM1.2256 mL6.1278 mL12.2557 mL61.2783 mL
10 mM0.6128 mL3.0639 mL6.1278 mL30.6391 mL
20 mM0.3064 mL1.5320 mL3.0639 mL15.3196 mL
50 mM0.1226 mL0.6128 mL1.2256 mL6.1278 mL
100 mM0.0613 mL0.3064 mL0.6128 mL3.0639 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords